GMM Pfaudler Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yqukrru609dgs226lovc393x.pdf

Key Takeaways


India Turnaround: What Recovered and Why

Tarak Patel: "I would just caution you to think about as I said, things are looking better. Things are looking more positive. Some volumes are coming back, prices are improving. But again, if you ask me are we out of the woods, yet I would still be a little bit more conservative."

Diversification: Breaking the Chemical and Pharma Dependence

Tarak Patel: "One of the main learning for management over the last couple of years has been that maybe as a company we are too focused on chemicals and pharma. And, with the cyclicality that comes with these markets, diversification becomes an important part of our strategy."

International Business: Softness and Structural Fixes

Tarak Patel: "When you buy a GMM Pfaudler reactor anywhere in the world, you should not really worry where it is made. At the end of the day, you get the right quality, you get the right price, and you get the right timeframe in terms of delivery."

Order Book and Revenue Conversion


Cost and Margin Trajectory


Guidance & Commitments

CommitmentSpecificsTimeline
Agrochemical investment recoveryInvestment to return, outlook more positive than six months ago"Over the next couple of quarters"
Chemical and pharma full turnaroundFull turnaround in these end-markets"A few more quarters"
Revenue mix targetChemical and pharma exposure to reduce to 50% of revenue"Next couple of years"
International near-term trajectoryNext quarter remains more or less like the last oneNext quarter
Long-term strategic plan3–4 year plan to be articulated to capital markets; currently 60–70% agreed upon, top management meeting planned next month"Next financial year"
Manufacturing footprint shiftReduce manufacturing in high-cost countries, ramp up India, use Brazil and China for low-cost glass-lined productionOngoing, "not quite there yet"
EBITDA marginImprove both margin percentage and absolute EBITDA volume vs current yearNext financial year (no number given)

Key Metrics

MetricQ3 FY25
Revenue₹801 cr, stable QoQ
EBITDAUp 3% QoQ
EBITDA margin12%, improved from 11.6% in Q2 FY25
EBITDA margin guidance11% to 12% for full year FY25
Order intake₹798 cr, up 5% QoQ
Order intake growth6% to 7% YoY across India and international, vs 18% to 20% in H1 FY25
9M order intake₹2,442 cr, up 13% vs 9M FY24
Order backlog₹1,740 cr, up 7% vs December 31, 2023
India standalone revenueDown 8% YoY
Revenue from chemical and pharma70% to 80% of total revenue
Services business share35% to 40% of international business, single digit in India
Mixing business share10% to 12% of total revenue in Q3 and 9M FY25
Heavy engineering growthDouble digit growth in 9M FY25
Net debt₹450 cr as of September 2024 balance sheet, with ₹950 cr debt and ₹400 cr cash
Net finance cost₹70 to 80 cr
Net debt costLess than 8% India and international combined
Other income₹25 cr in Q3 FY25, primarily on account of FX gain
Target margin profile15% across businesses